CA-AMAZENTIS
27.7.2020 15:07:04 CEST | Business Wire | Press release
Pioneering life sciences company, Amazentis , today announces new clinical findings and the commercial launch of Timeline Cellular Nutrition in the United States. After a decade of research by leading scientists and medical doctors, Timeline Nutrition is the first brand to offer Mitopure™, a highly pure form of Urolithin A proven to help counter age-associated cellular decline and improve muscular strength.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005447/en/
- A randomized, double-blind, placebo-controlled clinical trial (NCT03464500 ) in healthy middle-aged participants (40 to 65 years old) showed that 4 months of daily consumption of 500mg Mitopure™ (highly pure Urolithin A) led to a significant improvement in leg muscle strength.
- A separate randomized clinical trial (NCT04160312 ) conducted in healthy adults (18-80 years old) in the USA compared Urolithin A levels following consumption of Mitopure™ and pomegranate juice. It showed that 500mg of Mitopure™ delivers greater than 6X more Urolithin A compared to 8oz (240ml) of 100% pomegranate juice.
- Amazentis is launching the first product containing clinically proven Mitopure™ exclusively direct-to-consumer through the Timeline Nutrition website.
Many people begin to experience a loss in muscle strength starting in their 40s due to age-associated declines in cellular bioenergetics and mitochondrial function. Timeline is formulated with Mitopure™, a proprietary ingredient and highly pure form of Urolithin A. This bioactive is produced by the gut microbiome in only a limited portion of the population. Mitopure™ is the only compound shown to increase muscle function by activating the selective recycling of damaged mitochondria (the powerhouse of the cell) via an essential anti-aging process known as mitophagy.
“For the first time we have now shown that consuming Mitopure™ on a regular basis for 4 months triggers meaningful physiological changes in the body and significantly improves leg muscle strength” says Amazentis Chairman & Co-Founder, Patrick Aebischer, MD “this is a breakthrough in the translation of science-backed nutrition targeting muscle and healthy aging.”
Timeline is particularly effective because precisely calibrated doses of Mitopure™ deliver Urolithin A directly and activate mitophagy within the body—regardless of your diet or microbiome. This new clinical data showed that only 12% of participants had detectable levels of Urolithin A entering the study. Overall, participants showed a greater than 6-fold improvement in Urolithin A levels over 24 hours after consuming 500mg of Mitopure™ when compared to 8oz (240mL) of 100% pomegranate juice.
“At Amazentis, we’re dedicated to developing the next generation of nutrition products targeting cellular health and mitochondrial function. Now, more than ever, consumers appreciate the importance of staying healthy and maintaining muscle function. Timeline Nutrition brings together cutting-edge science with a great tasting product,” says Amazentis CEO and Co-Founder, Chris Rinsch, PhD.
Timeline’s first product comes in the form of a delicious Berry & Pomegranate flavored powder that can be mixed in with your daily smoothie, yogurt, and other breakfast favorites. Timeline is exclusively available for purchase online for consumers in the United States starting at $3.33 per day for a four-month supply. Visit www.timelinenutrition.com for more information.
* 500mg of Mitopure™ have been shown to (1) induce gene expression related to mitochondrial function and metabolism and (2) increase the strength of the hamstring leg muscle in measures of knee extension and flexion in overweight 40 to 65 year olds. Data from two randomized double-blind placebo-controlled human clinical trials.
About Timeline
Timeline Nutrition is the first brand to offer Mitopure™, a highly pure form of Urolithin A. This novel nutrition brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of nutrition that is backed by cutting edge science. As scientists, we know that physical decline from aging can’t be stopped. However, through its groundbreaking research, Timeline is committed to developing products designed to help reduce the impact of time on health. For more information, please visit www.timelinenutrition.com
.
About Mitopure™
Mitopure™ is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure™ has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure™ has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure™ has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit www.mitopure.com
.
About Amazentis
Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure™ Urolithin A in top peer reviewed scientific journals such as Nature Medicine
(doi:10.1038/nm.4132) and Nature Metabolism
(doi: 10.1038/s42255-019-0073-4). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™ linked to mitochondrial and cellular decline. For more information on Amazentis, please visit www.amazentis.com
.
Related Links
https://www.timelinenutrition.com
https://www.mitopure.com
https://www.amazentis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005447/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance and Alibaba Announce Alibaba's Expanded Participation in the VDP Pool2.7.2026 02:00:00 CEST | Press release
Access Advance LLC and Alibaba Group today announced that Alibaba has joined the Access Advance Video Distribution Patent Pool (VDP Pool) as a Licensee, securing a license to the pool's comprehensive coverage of HEVC, VVC, VP9, and AV1 codec technologies. The announcement marks a milestone in a multi-year collaboration between the two companies that spans the VVC Advance Patent Pool, where Alibaba participates as both a Licensor and Licensee, and the VDP Pool, where Alibaba joined as a Licensor in 2025. Alibaba's subsidiary Youku, one of China's leading streaming platforms, also joined the VDP Pool as a Licensee in 2025. Alibaba operates one of the world's most diverse video ecosystems, spanning a wide range of video-based services across e-commerce, entertainment, and digital media. As video has become central to how consumers shop, communicate, and access entertainment, the breadth of Alibaba's video operations reflects the kind of business model complexity the VDP Pool was designed
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia2.7.2026 01:58:00 CEST | Press release
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia -- Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA approval in people 12 years and older -- Regulatory review for label expansion underway in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. “Just as we redefined what is possible in cystic fibrosis, our ambition is to transform
Andersen Global styrker sine kompetencer inden for skat og global mobilitet i Tyskland2.7.2026 00:13:00 CEST | Pressemeddelelse
Andersen Global styrker sin tilstedeværelse gennem en samarbejdsaftale med Lohr and Company (L+C), der er en erfaren skatterådgivningsvirksomhed, der leverer praktiske og fleksible løsninger inden for skattecompliance, internationale skatteforhold, global mobilitet og transfer pricing. L+C har hovedkontor i Tyskland og er også til stede i Østrig og rådgiver store multinationale selskaber, familieejede virksomheder, familievirksomheder, fonde og formuende privatpersoner. L+C blev grundlagt i 2001 og har specialiseret sig i global mobilitet, opkøb og fusioner, international skattelovgivning, rapportering mellem lande og transfer pricing, herunder rapportering i henhold til Pillar 2. Derudover bistår L+C sine kunder med trusts og fonde, skattecompliance, løn- og regnskabsadministration samt privatøkonomisk rådgivning. "Samarbejdet med Andersen Global er et vigtigt skridt i udvidelsen af vores internationale kompetencer og styrker den værdi, vi skaber for kunder, der navigerer i stadig mer
Robinhood Chooses Morpho to Power New Earn Product1.7.2026 21:15:00 CEST | Press release
Morpho now powers the infrastructure behind some of the most widely used retail financial platforms in the United States, bringing more options for onchain yield to millions of customers through the apps they already use. Morpho, the open blockchain-based credit network, today announced it will power Robinhood’s new Earn product, enabling Robinhood's millions of eligible users more options to earn yield onchain via a self-custody wallet, directly within the Robinhood app. The product will roll out progressively to Robinhood's US customer base over the coming weeks. The Robinhood Earn product aims to provide risk-adjusted yield on idle balances using USDG, a dollar-pegged stablecoin. Morpho serves as the underlying credit network, Steakhouse Financial curates the vault infrastructure supporting the product, and Robinhood Chain acts as the settlement layer. The product is delivered through a seamless experience in the Robinhood app. Morpho operates as an open network on the blockchain. L
Photonics Innovators Worldwide Invited to Compete for SPIE Prism Awards1.7.2026 20:33:00 CEST | Press release
19th annual award honors exceptional new products transforming light-based technologies SPIE, the international society of optics and photonics, invites the optics and photonics community to apply for this year’s SPIE Prism Awards, which recognize outstanding new products making waves on the market. Honorees will be announced at the highly-anticipated award ceremony on 3 February 2027 at SPIE Photonics West in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701642411/en/ SPIE Prism Awards honor exceptional new products transforming optics and photonics technologies. These awards, dubbed the “Oscars of Photonics,” provide scientists and engineers in the optics and photonics industry the opportunity to showcase their contributions to the field. Finalists and winners receive extensive print, web, and onsite promotion at SPIE Photonics West, which draws more than 22,000 researchers and industry leade
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom